Phase I and pharmacokinetic study of the novel oral cell-cycle inhibitor Ro 31-7453 in patients with advanced solid tumors

Journal of Clinical Oncology

Volumn 22, Issue 16, 2004, Pages 3366-3374

  Dupont, Jakob ^a   Bienvenu, Bryan ^a   Aghajanian, Carol ^a   Pezzulli, Sandra ^a   Sabbatini, Paul ^a   Vongphrachanh, Phothisath ^a   Chang, Christine ^a   Perkell, Christina ^a   Ng, Kenneth ^a   Passe, Sharon ^a   Breimer, Lars ^a   Zhi, Jianguo ^a   DeMario, Mark ^a   Spriggs, David ^a   Soignet, Steven L ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DRUG METABOLITE; RO 317453; UNCLASSIFIED DRUG; INDOLE DERIVATIVE; RO 31 7453; RO 31-7453;

ADVANCED CANCER; ALOPECIA; ARTICLE; BLOOD SAMPLING; BONE MARROW SUPPRESSION; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER MORTALITY; CELL CYCLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG ABSORPTION; DRUG DETERMINATION; DRUG DOSE REGIMEN; DRUG EXCRETION; DRUG FATALITY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HUMAN; LINEAR SYSTEM; LIVER FUNCTION TEST; LUNG CARCINOMA; NAUSEA; NEUTROPENIA; OBSERVATION; OVARY CARCINOMA; PANCREAS CARCINOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SEPSIS; SINGLE DRUG DOSE; SOLID TUMOR; STOMATITIS; URINALYSIS; VOMITING; ADULT; AGED; CHEMICALLY INDUCED DISORDER; FEMALE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM; ORAL DRUG ADMINISTRATION; THROMBOCYTOPENIA;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; INDOLES; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; THROMBOCYTOPENIA;

EID: 4344601239     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.12.007     Document Type: Article

References (21)

1. Senderowicz AM, Sausville EA: Preclinical and clinical development of cyclin-dependent kinase modulators. J Natl Cancer Inst 92:376-387, 2000
2. Sherr CJ: Cancer cell cycles. Science 274:1672-1677, 1996
3. Hartwell LH, Kastan MB: Cell cycle control and cancer. Science 266:1821-1828, 1994
4. Harper J, Elledge S: CDK inhibitors in development and cancer. Curr Opin Genet Dev 6:56-64, 1996
5. Cordon-Cardo C: Mutations of cell cycle regulators: Biological and clinical implications for human neoplasia. Am J Pathol 147:545-560, 1995
6. Carlson BA, Dubay MM, Sausville EA, et al: Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res 56:2973-2978, 1996
7. Wang Q, Fan S, Eastman A, et al: UCN-01: A potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst 88:956-965, 1996
8. Meijer L, Kim SH: Chemical inhibitors of cyclin-dependent kinases. Methods Enzymol 283:113-128, 1997
9. Carlson B, Lahusen T, Singh S, et al: Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res 59:4634-4641, 1999
10. Hashemolhosseini S, Nagamine Y, Morley SJ, et al: Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J Biol Chem 273:14424-14429, 1998
11. Yamada H, Iwase S, Nagai M, et al: Herbimycin A down-regulates messages of cyclin D1 and c-myc during erythroid differentiation of K562 cells. Int J Hematol 65:31-40, 1996
12. Schwartz GK, O'Reilly E, Ilson D, et al: Phase 2 study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J Clin Oncol 19:1985-1992, 2001
13. Sausville EA, Arbuck SG, Messmann R, et al: Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J Clin Oncol 19:2319-2333, 2001
14. Schiff PB, Fant J, Horwitz SB: Promotion of microtubule assembly in vitro by Taxol. Nature 277:665-667, 1979
15. Bollag DM, McQueney PA, Zhu J, et al: Epothilones, a new class of microtubulestabilizing agents with a Taxol-like mechanism of action. Cancer Res 55:2325-2333, 1995
16. Investigational Brochure: Ro 31-7453. Nutley, NJ, Hoffmann-La Roche Inc. 1999
17. Dhingra U, Thomas M, Bertasso A, et al: Identification and preclinical characterization of metabolites of Ro 31-7453, a new cell-cycle inhibitor. Proc Am Assoc Cancer Res 41:31, 2000 (abstr 199)
18. Simon R, Freidlin B, Fubinstein L, et al: Accelerated titration design for Phase I clinical trials in oncology. J Natl Cancer Inst 89:1138-1147, 1997
19. Tan AR, Headlee D, Messmann, et al: Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms. J Clin Oncol 20:4074-4082, 2002
20. Luistro LL: Antiproliferative and antitumor effects of Ro 31-7453 and gemcitabine alone and in combination against non-small cell lung carcinoma (NSCLC) models. Proc Am Assoc Cancer Res 42:82, 2001 (abstr 440)
21. Mortensen JH, et al: Antiproliferative and antitumor effects of Ro 31-7453 and capecitabine (Xeloda) alone and in combination against mammary and colorectal xenograft models. Proc Am Assoc Cancer Res 42:297, 2001 (abstr 1596)